Grant Zeng, CFA
Research analyst, CFA, biotech, small-cap

Sorrento Therapeutics: Has The Potential To Become Next Abraxis

Sorrento Therapeutics (NASDAQ:SRNE) is a development stage biopharmaceutical company focused on the development and commercialization of proprietary drug therapeutics for cancer and cancer pain. The company is also developing therapeutic products for other indications, including inflammation, metabolic disorders, and infectious diseases.

Sorrento's pipeline consists of lead oncology product candidate Cynviloq™, a polymeric micellar nanoparticle paclitaxel formulation, resiniferatoxin (RTX), a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor for cancer pain, as well as fully human therapeutic antibodies derived from its proprietary G-MAB® library platform and antibody drug conjugates (ADCs).

(click to enlarge)(click to enlarge)

Cynviloq, Next Generation of Abraxane®

Cynviloq is Sorrento's lead cancer drug candidate. Cynviloq™ is a next-generation nanoparticle

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details